TABLE 1

Characteristics of the male rAAV-HBV–infected mice study design

All individual groups (n=6) were divided into two cohorts (n=3) for blood sampling within the first 4 blood sampling occasions (within 4 hours after dosing). The first cohort underwent blood sampling at the first and the third sampling timepoints, the second cohort underwent blood sampling at the second and the fourth sampling timepoints.

Study Group	N	Route of Administration	JNJ-73763989 Dose (mg/kg)	PK Sampling Regimen (Hours Since Dosing)
1	6	IV	10	0.25, 0.75, 2, 4, and 168^a
2	24	SC	10	0.5, 1, 2, 4, 24^a,^b, 168^a^,^b, 504^a^,^b, and 1008^a^,^b
3	6	SC	3	0.5, 1, 2, 4, and 1008^a
4	6	SC	1	0.5, 1, 2, 4, and 1008^a

IV, intravenous; SC, subcutaneous.
^aSampling time point after which the animal was sacrificed, liver PK data only available at final time point.
^bAnimals from study group 2 were block randomized into cohorts of n = 6 animals and sacrificed at different time points to obtain semilongitudinal liver PK data.